Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2010-11-10 09:20:37)
Á¦¸ñ [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡¼­ PNA-Mediated PCR ClampingÀ» ÀÌ¿ëÇÑ EGFR µ¹¿¬º¯ÀÌ ºÐ¼®¹ý
³»¿ë

* ´ëÇÑ °áÇÙ ¹× È£Èí±â ÇÐȸ¿¡¼­ PNA Clamp¢â EGFR mutation detection kit¸¦ »ç¿ëÇÏ¿© °Ô½ÃÇÑ ³í¹®ÀÔ´Ï´Ù.

Á¦¸ñ(±¹¹®) :
¿øÀú : ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡¼­ PNA-Mediated PCR ClampingÀ» ÀÌ¿ëÇÑ EGFR µ¹¿¬º¯ÀÌ ºÐ¼®¹ý

Á¦¸ñ(¿µ¹®) :
Original Article : PNA-Mediated PCR Clamping for the Detection of EGFR
Mutations in Non-Small Cell Lung Cancer

ÀúÀÚ :
À̰迵 ( Kye Young Lee ) , ±èÈñÁ¤ ( Hee Joung Kim ) , ±è¼øÁ¾ ( Sun Jong Kim ) , À¯±¤ÇÏ ( Gwang Ha Yoo ) , ±è¿øµ¿ ( Won Dong Kim ) , ¿À¼­¿µ ( Seo Young Oh ) , ±è¿Ï¼· ( Wan Seop Kim )

Ãâó :
´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ , Tuberculosis and Respiratory Diseases | 69±Ç 4È£ 271 ~ 278,   ÃÑ 8 pages 

¹ßÇ࿬µµ : 2010

ÁÖÁ¦Å°¿öµå :
Peptide Nucleic Acids, Receptor, Epidermal Growth Factor, Carcinoma, Non-Small-Cell Lung

ÃÊ·Ï(¿µ¹®) :
Background: Recent studies have demonstrated that the epidermal growth factor receptor (EGFR) genotype is the most important predictive marker to EGFR-tyrosine kinase inhibitors (TKIs) and first-line gefitinib treatment will be approved in the near future for use in non-small cell lung cancer (NSCLC) patients with the EGFR mutation. Direct sequencing is known to be the standard for detecting EGFR mutations; however, it has limited sensitivity. Peptide nucleic acids (PNA)-mediated PCR clamping method is a newly introduced method for analyzing EGFR mutations with increased sensitivity and stability. Methods: A total of 71 NSCLC patients were analyzed for EGFR mutations using the PNA-mediated PCR clamping technique. Sixty-nine patients were analyzed for clinicopathologic correlation with EGFR genotype; 2 patients with indeterminate results were excluded. In order to determine EGFR-TKI drug response, 57 patients (42 gefitinib, 15 erlotinib) were included in the analysis. Results: The EGFR mutation rate was 47.8%. Being female, a non-smoker, and having adenocarcinoma were favorable clinicopathologic factors, as expected. However, more than a few smokers (33.3%), male (28.1%), and patients with non-adenocarcinoma (28.6%) had the EGFR mutation. Having a combination of favorable clinicopathologic factors did not increase the EGFR mutation rate significantly. Drug response to EGFR-TKIs showed significant differences depending on the EGFR genotype; ORR was 14.3% for wild type vs 69.0% for mutant type; DCR is 28.6% for wild type vs 96.6% for mutant type. The median EGFR-TKI treatment duration is 7.6 months for mutant type group and 1.4 months for wild type group. Conclusion: EGFR genotype determined using the PNA-mediated PCR clamping method is significantly correlated with the clinical EGFR-TKI responses and PNA-mediated PCR.

* ÷ºÎÆÄÀÏ ÂüÁ¶¹Ù¶ø´Ï´Ù.
* Link to - CLICK


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 30452
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29357
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6215
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 21121
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8562
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1322
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5963
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6246
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25432
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14469
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22389
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3534
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14306
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1314
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4175
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8971
¢º           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14625
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1318
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 4039
 

< 1 2 3 >